Europeanhhm

MemorialCare Heart & Vascular Institute at Long Beach Medical Center Performs First Transcatheter Aortic Valve Implantation with Navitor Titon 35mm Valve in Southern California

Saturday, June 22, 2024

MemorialCare Heart & Vascular Institute at Long Beach Medical Center achieved a significant milestone by performing Southern California's first implantation of a 35mm Abbott Titan Navitor Valve during a Transcatheter Aortic Valve Implantation (TAVI) procedure.

This procedure is crucial for patients suffering from severe aortic stenosis who are deemed high-risk for traditional open-heart surgery.

The Navitor valve offers a minimally invasive alternative, reducing hospital stays, lowering infection risks, and expediting recovery times.

"This transformative period for our heart and vascular institute,"said Chief of Cardiology at MemorialCare Heart & Vascular Institute.

"At Long Beach Medical Center, we have always prioritized personalized patient care. The Navitor Titan 35mm Valve has enabled us to offer a minimally invasive treatment option to high-risk patients suffering from severe aortic stenosis."

The Navitor valve, recently approved by the U.S. Food and Drug Administration for TAVI procedures, stands out due to its enhanced hemodynamic performance and user-friendly design compared to other available heart valve devices.

The intuitive design of the Navitor TAVI System expands treatment possibilities to patients who were previously ineligible for Transcatheter Aortic Valve Replacement due to anatomical constraints.

Heart valve disease impedes the heart's ability to pump blood effectively throughout the body. The Navitor TAVI System has demonstrated significant improvements in blood flow for patients suffering from symptomatic severe aortic stenosis, facilitating a quicker return to normal cardiac function.

"MemorialCare remains committed to delivering state-of-the-art, patient-centric care to our community, and this pioneering procedure underscores our dedication to excellence in patient outcomes," Director of Aortic and Arrhythmia Surgery at MemorialCare Heart & Vascular Institute.

Extensively tested, the Navitor TAVI System has shown exceptional 30-day outcomes in patients with symptomatic severe aortic stenosis, boasting a 0% incidence of moderate or severe paravalvular leak (PVL), 1.9% all-cause mortality rate, 1.9% risk of disabling stroke, and 4.2% incidence of major vascular complications, affirming its outstanding safety and effectiveness in TAVR procedures.

 

 

 

 

 

Source: prnewswire.com

Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital Congress